Bullfrog AI Holdings, Inc. Warrants - BFRGW STOCK NEWS

BullFrog AI Holdings, Inc. announced early results from its collaboration with the Lieber Institute for Brain Development that could revolutionize the understanding and treatment of psychiatric disorders. The collaboration has successfully stratified brain expression data, offering unprecedented insights into psychiatric conditions. The proprietary data from LIBD included gene expression data from over 2,800 brain samples encompassing schizophrenia, bipolar disorder, major depressive disorder, and non-psychiatric control brains. Utilizing graph analytics, BullFrog AI and LIBD have, for the first time, clustered subjects based solely on their biological data, independent of their behavioral diagnoses. This innovative approach has yielded promising insights, highlighting distinct differences and similarities in biological pathways across various brain disorders. The market opportunity for new treatments in psychiatric disorders is vast and underserved, presenting a potential paradigm shift in treatment approaches.

BullFrog AI Holdings, Inc. (NASDAQ: BFRG; BFRGW) has announced that the Australian Patent Office has issued Patent No. 2019216757 protecting the Company’s novel prodrugs derived from mebendazole and their use in treating cancers and other diseases. This patent further strengthens the intellectual property protection of BF-223 and related compounds, including positive results from a preclinical study demonstrating that BF-223 has anticancer activity in an animal model for glioblastoma. The patented compounds exhibit improved solubility and oral bioavailability relative to the parent drug, addressing a key difficulty associated with the potential use of mebendazole for oncology indications. The company is looking forward to working with strategic partners to monetize this promising asset for the treatment of glioblastoma and other oncology indications.

BullFrog AI Holdings, Inc. (NASDAQ: BFRG; BFRGW) announces CEO's participation in Webull LIVE! Healthcare Webinar

BullFrog AI Holdings, Inc. (NASDAQ: BFRG; BFRGW) has had an extraordinary year, marked by progress, innovation, and value-adding events. The company successfully completed an $8.4 million IPO listing on Nasdaq and secured an exclusive partnership with Lieber Institute for Brain Development. BullFrog AI has also made significant strides in drug development, including identifying drug targets for colorectal cancer and initiating pre-clinical studies for liver disease and obesity drug candidates. The company has strengthened its intellectual property, licensed improvements to its AI algorithms, and recorded its first earned revenue in the third quarter. BullFrog AI's CEO, Vin Singh, is optimistic about the future, emphasizing the company's focus on securing business and driving revenue through external contracts and partnerships.

BullFrog AI Holdings, Inc. (NASDAQ: BFRG; BFRGW) announced the launch of a preclinical study led by Dr. Randy Seeley to evaluate the efficacy of its drug candidate BF-114 in treating obesity, NAFLD, and NASH. The study is expected to be completed in Q2 2024 and aims to complement the company’s AI platform for identifying new pathways to target obesity and metabolic diseases. With the market for obesity drugs projected to exceed $77 billion by 2030, the potential impact of BF-114 on these conditions is significant.

RedChip Companies will air interviews with ASP Isotopes Inc. and BullFrog AI Holdings, Inc. on The RedChip Small Stocks Big Money® Show, a sponsored program on Bloomberg TV. ASP Isotopes CEO provides a corporate update, highlighting the completion of the first manufacturing plant and securing multiple supply agreements. BullFrog AI Founder and CEO discusses the company's use of machine learning in drug development.

BullFrog AI Holdings, Inc. to present at Benzinga's All Access investor event

BullFrog AI identifies potential therapeutic targets for colorectal cancer using AI-driven platform

BullFrog AI's drug BF-223 shows anti-cancer activity against glioblastoma in animal model, with improved properties compared to BF-222